Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size & Share Analysis - By Product Type, By Application, By Region - Forecasts (2024

The "Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market" is focused on controlling cost, and improving efficiency. Moreover, the reports offer both the demand and supply aspects of the market. The Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors market is expected to grow annually by 12.7% (CAGR 2024 - 2031).

This entire report is of 164 pages.

Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Introduction and its Market Analysis

The Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors market research reports indicate a growing market demand for these drugs, which are used to treat type 2 diabetes by inhibiting glucose reabsorption in the kidneys. The target market for SGLT 2 Inhibitors includes individuals with diabetes who are looking for effective treatment options. Major factors driving revenue growth in this market include increasing prevalence of diabetes, rising healthcare expenditure, and technological advancements in drug development. Leading companies operating in the Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors market include Eli Lilly, Boehringer Ingelheim, Janssen Pharmaceuticals, Kotobuki Pharmaceutical, Astellas, Bristol Myers Squibb, and AstraZeneca. The report's main findings highlight the market's potential for growth and recommend strategic investment in research and development to capitalize on this opportunity.

Get a Sample PDF of the Report: https://www.reliableresearchreports.com/enquiry/request-sample/1696257

The sodium/glucose cotransporter 2 (SGLT 2) inhibitors market is experiencing significant growth, with key players such as Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), and Suglat (Ipragliflozin) leading the way. These medications are commonly used in hospitals, medical research institutes, and other healthcare settings to treat type 2 diabetes.

Regulatory and legal factors specific to the market conditions play a crucial role in shaping the landscape for SGLT 2 inhibitors. The FDA has approved these drugs for use in patients with type 2 diabetes, but there are ongoing debates regarding their safety and potential side effects. Manufacturers must navigate complex regulatory requirements to bring these drugs to market and ensure their continued compliance with changing regulations.

Overall, the SGLT 2 inhibitors market is poised for continued growth as the prevalence of diabetes continues to rise worldwide. With advancements in medical research and technology, there is great potential for new innovative therapies to further improve patient outcomes and quality of life.

Top Featured Companies Dominating the Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market

The Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market is highly competitive with several key players operating in the industry. Some of the prominent companies in this market are Eli Lilly, Boehringer Ingelheim, Janssen Pharmaceuticals, Kotobuki Pharmaceutical, Astellas, Bristol Myers Squibb, and AstraZeneca.

These companies are actively involved in developing and marketing SGLT 2 inhibitors for the treatment of type 2 diabetes. They invest heavily in research and development to bring innovative therapies to the market that can effectively manage blood sugar levels in diabetic patients. These companies also collaborate with healthcare providers, physicians, and patient organizations to raise awareness about the benefits of SGLT 2 inhibitors and promote their usage.

Eli Lilly, for example, markets empagliflozin under the brand name Jardiance, which is one of the top-selling SGLT 2 inhibitors in the market. Boehringer Ingelheim and Eli Lilly have also collaborated to develop and market empagliflozin as a combination therapy with metformin.

In terms of sales revenue, Eli Lilly reported revenues of $ billion in 2020, while Boehringer Ingelheim reported revenues of €19.5 billion in the same year. Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, reported revenues of $42.2 billion in 2020. These figures highlight the significant market presence and growth potential of these companies in the Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market.

Eli Lilly
Boehringer Ingelheim
Janssen Pharmaceuticals
Kotobuki Pharmaceutical
Astellas
Bristol Myers Squibb
AstraZeneca

Get a Sample PDF of the Report: https://www.reliableresearchreports.com/enquiry/request-sample/1696257

Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Analysis, by Type:

Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)

Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors such as Invokana, Jardiance, Farxiga/Forxiga, and Suglat work by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. This helps lower blood sugar levels in patients with type 2 diabetes. These medications have gained popularity in the market due to their efficacy in lowering blood sugar levels, weight reduction benefits, and potential cardiovascular benefits. The demand for SGLT 2 Inhibitors is expected to continue growing as more patients and healthcare providers recognize the clinical benefits of these medications.

Inquire or Share Your Questions If Any Before the Purchasing This Report -https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1696257

Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Analysis, by Application:

Hospital
Medical Research Institute
Other

SGLT 2 inhibitors are utilized in hospitals to manage hyperglycemia in diabetic patients. In medical research institutes, they are studied for their potential in reducing cardiovascular events in diabetic individuals. Other applications include their use in primary care settings to improve glycemic control and reduce the risk of diabetic complications. The fastest growing application segment in terms of revenue is in the treatment of type 2 diabetes, as SGLT 2 inhibitors have been shown to effectively lower blood glucose levels by inhibiting glucose reabsorption in the kidneys, leading to improved outcomes for diabetic patients.

Purchase this Report (Price 3500 USD for a Single-User License): reliableresearchreports.com/purchase/1696257

Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Industry Growth Analysis, by Geography:

North America:

United States
Canada

Europe:

Germany
France
U.K.
Italy
Russia

Asia-Pacific:

China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia

Latin America:

Mexico
Brazil
Argentina Korea
Colombia

Middle East & Africa:

Turkey
Saudi
Arabia
UAE
Korea

The Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors market is expected to experience significant growth in North America, particularly in the United States and Canada, as well as in Europe, with Germany, France, the ., and Italy leading the market. In the Asia-Pacific region, countries like China, Japan, South Korea, India, and Australia are expected to dominate the market. Latin America, including Mexico, Brazil, Argentina, and Colombia, is also expected to see growth, as well as the Middle East & Africa, including Turkey, Saudi Arabia, the UAE, and Korea. North America is expected to dominate the market with a market share of approximately 40%, followed by Europe with a market share of 30%. Asia-Pacific is expected to have a market share of 20%, while Latin America and the Middle East & Africa are expected to have a market share of 5% each.

Purchase this Report (Price 3500 USD for a Single-User License): reliableresearchreports.com/purchase/1696257

Check more reports on reliableresearchreports.com

Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size & Share Analysis - By Product Type, By Application, By Region - Forecasts (2024 - 2031)